Article

AAN 2012: Interview with Dr. Zigmond about Exercise and Parkinson's Disease Study [Podcast]

In this interview, Michael Zigmond, PhD, previews his lecture to be given at this year's AAN Annual Meeting. Zigmond explains how he became involved with studying Parkinson's disease (PD), research with exercise and PD, and what his intentions are with helping to fight this disease.

Professor of Neurology

In this interview, Michael Zigmond, PhD, at theUniversity of Pittsburgh, discusses why he became involved with studying Parkinson’s disease and his research on exercise and Parkinson’s disease which he will be presenting at this year's AAN conference.

When asked about how he began his research in Parkinson's disease, Zigmond said, "I became interested in catecholamines, which includes dopamine and norepinephrine primarily, as a graduate student. There was evidence that they were affected by stress and I was interested in looking at the adaptive effects of stress."

It was upon collaborating with colleague when Zigmond explained how he "discovered that... physicial exercise was what we would call 'neuroprotective.' If you had animals exercise before you expose them to a toxin like 6-Hydroxydopamine, the effects of the toxin on the animals' behavior and on the dopamine neurons themselves was reduced."

Related Videos
Marcelo Kugelmas, MD | Credit: South Denver Gastroenterology
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.